Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Avidity Biosciences Inc.
RNA | US
13.49
USD-0.36
-2.60%
RNA | US
Loading StockChartView...
About Avidity Biosciences Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
13.49
Open
13.78
High
13.78
Low
13.46
Avidity Biosciences Inc. a biopharmaceutical company engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1 a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences Inc. was incorporated in 2012 and is headquartered in San Diego California.
View LessRNA | US
Risk
49.0
Sharpe
-0.57
Luna's Score
36/100
Recommendation
Sell
Luna says (RNA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
66.9%1 month
49.0%3 months
164.0%6 months
132.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.74
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-5.72
Ent. to rev.
424.10
PEG
-
Other Fundamentals
EBITDA
-282.67M
MarketCap
1.59B
MarketCap(USD)
1.59B
Div. yield
-
Op. margin
-4.04K
Erngs. growth
-
Rev. growth
-11.70
Ret. on equity
-28.36
Short ratio
8.43
Short perc.
15.45
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
2.17
Range1M
2.17
Range3M
61.11
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.41
Price X volume
2.65M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.72 | 0.53 | Cheaper |
| Ent. to Revenue | 424.10 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.74 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 164.05 | 72.80 | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 1.59B | 3.66B | Emerging |
